# Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy

> **NCT02377648** · PHASE4 · COMPLETED · sponsor: **Universita di Verona** · enrollment: 34 (actual)

## Conditions studied

- Cardiac Allograft Vasculopathy

## Interventions

- **DEVICE:** Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)

## Key facts

- **NCT ID:** NCT02377648
- **Lead sponsor:** Universita di Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-09
- **Final completion:** 2020-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02377648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02377648, "Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02377648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*